Recent Advances in Diagnosis, Treatment and Prognosis of Giant Cell Tumor of the Bone
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (30 June 2024) | Viewed by 2813
Special Issue Editor
Special Issue Information
Dear Colleagues,
Giant cell tumor (GCT) of the bone is a locally aggressive and rarely metastasizing primary bone tumor.
The controversial treatment is decided by the balance between an adequate surgical margin and sufficient adjacent joint function.
Curettage with a high-speed burr and local adjuvants is the most indicated treatment for active lesions, but with a high local recurrence rate. Conversely, en bloc resection for aggressive lesions have lower local recurrence rates, but increased morbidity and possible functional impairment.
Denosumab—a monoclonal antibody that inhibits RANKL—is considered to be a new option for the treatment of locally advanced GCT. Even though denosumab downstages the GCT, concerns have been raised for the reactivation of the disease after termination of the treatment. Moreover, there are still concerns regarding the most appropriate surgery and for requirement of bone resections despite the use of denosumab.
We would like to invite physicians and researchers involved in this field to contribute observations and results to this Special Issue.
Dr. Laura Campanacci
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- giant cell tumor of the bone
- curettage
- resection
- denosumab
- biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
